12. All the claims of the '850 application and all
the claims of the '931 application correspond to the count
(Paper 1 at 15).
General explanation of the involved technology
13. The Huang and Prasit compounds are said to be
selective cyclooxygenase-2 ("COX-2") inhibitors.
14. The '850 specification and the '931
specification each contain a general explanation of the
technology as summarized below ('850 at 1-2 and '931 at 1-2).
15. The formation of prostaglandins in the body is
believed to be catalyzed, in part, by the enzyme
cyclooxygenase. Prostaglandins have been implicated in tissue
inflammation.
16. It is believed that cyclooxygenase inhibitors
function as anti-inflammatory agents by inactivating the
enzymatic activity of cyclooxygenase.
17. There are at least two types of cyclooxygenase
inhibitors, i.e., COX-1 inhibitors and COX-2 inhibitors.
18. COX-2 inhibitors are believed to have the same
anti-inflammatory effect as COX-1 inhibitors; however, COX-2
inhibitors seem to have fewer and less severe negative
gastrointestinal side effects (e.g., ulcer formation) than
COX-1 inhibitors.
9
Page: Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
Last modified: November 3, 2007